Stock FIBROCELL SCIENCE INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Fibrocell Science Inc OTC Bulletin Board

Equities

US3157211000

End-of-day quote OTC Bulletin Board
Other stock markets
- USD - Intraday chart for Fibrocell Science Inc
2019 Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index CI
2019 Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fibrocell Science : Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
AQ
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from S&P TMI Index
CI
FIBROCELL SCIENCE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Fibrocell Science, Inc.(NasdaqGM:FCSC) dropped from NASDAQ Composite Index
CI
Castle Creek Pharmaceutical Holdings, Inc. completed the acquisition of Fibrocell Science, Inc..
CI
FIBROCELL SCIENCE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
FIBROCELL SCIENCE, INC. : Other Events (form 8-K)
AQ
Fibrocell Science, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
CI
FIBROCELL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fibrocell Science, Inc. - FCSC
BU
Castle Creek Pharmaceutical Holdings, Inc. entered into a definitive agreement to acquire Fibrocell Science, Inc. for $63.3 million.
CI
Fibrocell Science, Inc Appoints Sean D. Buckley as Chief Financial Officer
CI
Fibrocell Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
GL
Fibrocell Science, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
CI
Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
GL
Fibrocell Science, Inc. Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB
CI
Fibrocell Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019
CI
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
GL
Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
CI
Fibrocell Science, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018
CI
Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Fibrocell Science Inc